The difference between a promising therapy and a transformative one often comes down to delivery. Continuity Biosciences builds precision delivery platforms that close the gap between what a therapy can do and what a patient actually experiences. Our adaptive, therapy-agnostic technologies support applications across oncology, chronic disease, and medical aesthetics, spanning small molecules, biologics, and cell-based therapies. We don't build around a single drug or indication. We build infrastructure for better therapeutic delivery, wherever it matters most. Our science is rooted in research from Houston Methodist, University of Miami, University of North Carolina. Our collective work spans 135 publications and 80 patents—not as a measure of the past, but as a foundation for what comes next. We welcome conversations with partners, investors, and collaborators. Reach out or follow along as we build.
我们正在追踪 Continuity Biosciences, LLC 的市场扩张
Continuity Biosciences, LLC 的国际扩张与竞争对手的对比情况
Continuity Biosciences, LLC你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Continuity Biosciences, LLC你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Continuity Biosciences启动第一期胰腺癌临床试验,使用离子电渗平台直接向肿瘤输送吉西他滨,在西弗吉尼亚大学和密歇根大学医学中心招募患者。
Continuity Biosciences在WVU Medicine和密歇根大学等主要学术中心启动第一期试验,评估通过IOP平台输送吉西他滨治疗胰腺癌。
Continuity Biosciences 在顶尖学术医疗中心启动首次人体第一阶段临床试验,评估通过其离子电渗肿瘤平台输送吉西他滨治疗胰腺癌。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Continuity Biosciences, LLC 的业务、市场和增长信号的快速解答。
